Galena Biopharma

Galena Biopharma is a biotechnology company dedicated to the discovery, development, and commercialization of therapeutic treatments that address unmet medical needs using targeted biotherapeutics. The company is focused on developing cancer treatments using peptide-based immunotherapy products, including its lead candidate NeuVaxTM (E75) for the treatment of breast cancer and other tumors. NeuVax is a peptide-based immunotherapy designed to reduce breast cancer recurrence in patients with low to intermediate HER2-positive breast cancer who are not eligible for trastuzumab (Herceptin; Genentech/Roche).